Krystal Biotech (KRYS) EBIT (2016 - 2026)

Krystal Biotech has disclosed EBIT across 11 years of filings, most recently posting $53.7 million for Q1 2026.

• EBIT for Q1 2026 came in at $53.7 million, up 48.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $178.6 million (up 64.4% YoY), and the FY2025 annual result was $161.3 million, up 145.32% from the prior year.
• EBIT came in at $53.7 million for Q1 2026 at Krystal Biotech, up from $44.3 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $53.7 million in Q1 2026 to a low of -$50.2 million in Q1 2022.
• The 5-year median for EBIT is $3.2 million (2023), against an average of $1.5 million.
• Across the five-year window, EBIT plunged 249.91% in 2022 and surged 1173.86% in 2024, its largest moves.
• Krystal Biotech's EBIT stood at -$34.8 million in 2022, then jumped by 109.34% to $3.2 million in 2023, then soared by 1173.86% to $41.4 million in 2024, then increased by 7.0% to $44.3 million in 2025, then climbed by 21.28% to $53.7 million in 2026.
• The last three EBIT figures came in at $53.7 million (Q1 2026), $44.3 million (Q4 2025), and $41.4 million (Q3 2025), per Business Quant data.